- Teva Pharmaceuticals and mAbxience have entered a global licensing agreement for developing an anti-PD-1 oncology biosimilar.
- This marks the second agreement between the two companies, enhancing their collaboration established in April 2024.
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., has announced a new global licensing agreement with mAbxience, a Fresenius Kabi majority-owned group. This agreement focuses on the development of an anti-PD-1 oncology biosimilar candidate. It is the second collaboration between the two companies, following their initial partnership established in April 2024.
The agreement grants exclusive rights to develop the biosimilar in multiple markets, including Europe and the United States. This initiative aligns with mAbxience’s strategy for global expansion and supports Teva’s “Pivot to Growth” strategy by adding a new biosimilar to its extensive portfolio. Both companies aim to provide cost-effective and high-quality biosimilar treatments to meet critical needs in oncology care.
Under the terms of the agreement, mAbxience will lead the development and production of the biosimilar at its cGMP-compliant facilities located in Spain and Argentina. Meanwhile, Teva will manage regulatory approvals and oversee the commercialization process in the designated markets, ensuring that the treatment is accessible to patients worldwide.
Angus Grant, PhD, Executive Vice President of Business Development at Teva, stated: “We are excited to deepen our collaboration with mAbxience. This agreement not only strengthens our alliance but also highlights our shared dedication to expanding access to critical oncology treatments.”
Jurgen Van Broeck, CEO of mAbxience, noted that this second collaboration signifies the strength of their partnership. He remarked: “This agreement reinforces our commitment to making high-quality biosimilars accessible and improving healthcare outcomes on a global scale.”
Overview of outsourcing trends 
